Physician profile
John Mikhail
NPI 1205173762
$10,534.43
in general payments reported to CMS, 2019-2025
31 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $552 · 2021: $832 · 2022: $1,866 · 2023: $1,735 · 2024: $3,304 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,489 · Consulting Fee: $1,464 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,488.53 |
| Consulting Fee | $1,464.00 |
| Education | $260.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,516.39 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,955.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,895.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,362.40 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $568.99 | 2019-2025 | Dupixent |
| Amgen INC. | $379.87 | 2022-2025 | Tezspire |
| Insmed, INC. | $231.96 | 2022-2025 | Arikayce |
| United Therapeutics Corporation | $203.83 | 2023-2025 | Tyvaso, Tyvaso |
| Philips North America LLC | $159.25 | 2019-2025 | Vest Therapy Und |
| Sanofi-Aventis U.S. LLC | $156.98 | 2022-2023 | |
| Mylan Specialty L.P. | $150.95 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $140.54 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $125.60 | 2019-2024 | Uptravi |
| Intuitive Surgical, INC. | $94.22 | 2022 | |
| Inspire Medical Systems, INC. | $72.04 | 2023-2024 | Inspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $51.18 | 2019 | |
| Grifols USA, LLC | $51.18 | 2019-2024 | Prolastin-C Liquid |
| Boston Scientific Corporation | $47.45 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.28 | 2022-2025 | Aralast |
| Pfizer INC. | $45.20 | 2022-2023 | |
| Genentech USA, INC. | $42.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $39.62 | 2020-2021 | |
| Vifor Pharma, INC. | $33.92 | 2022-2023 | Veltassa |
| Verona Pharma, INC. | $33.56 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $32.99 | 2025 | Yupelri |
| Electromed, INC. | $20.37 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.65 | 2023 | Purified Cortrophin Gel |
| Apria Healthcare LLC | $17.02 | 2021 | |
| Circassia INC. | $13.72 | 2019 | |
| Harmony Biosciences LLC | $13.03 | 2021 | |
| Covis Pharma Gmbh | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mikhail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.